Target: EGFR
The epidermal growth factor receptor (EGFR; ERBB1; HER1) is an important target in oncology as its overexpression may lead to uncontrolled cell growth.
Today, there are kinase inhibitors and monoclonal antibodies that are used as therapies in cancers ranging from adenocarcinoma to glioblastoma. As always, there’s still room for improvement.
So, we’ve made our own using AI.
One of our best candidates (TUPEGFR-003, in yellow) versus cetuximab (in grey). EGFR shown in white.
Various binding affinity metrics from existing therapeutic anti-EGFR antibodies versus our diffused candidates.
